A cost-benefit analysis estimates that for every RM1 saved from drug price controls, about RM4.30 is lost to Malaysia, besides decreased health care access and poorer health outcomes for Malaysians.
The Pharmaceutical Association of Malaysia and affiliates of health care industry partner with the government of Malaysia to undertake a cost-benefit analysis study to build a constructive path for future health care policies.